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Abstract
Objectives: Treatment rollout has dramatically improved life expectancy for people with HIV and AIDS. Women represent
a substantial proportion of patients in the UK (approximately one-third of patients in care are female according to the
HIV Annual Report 2014). This study examines psychosocial and biomedical issues for women diagnosed with HIV in
the UK, comparing those above and below 45 years of age to examine menopause and ageing issues.
Methods: Consecutive clinic attenders in a large outpatient London HIV clinic were invited to participate in the study.
Data were available for 170 (68%) women. In 57 women above the age of 45 data were available regarding menopause
detailed insights.
Results: Compared with women aged under 45, women >45 years old were significantly less likely to be in a relationship
(P=0.01), had higher anxiety scores (P=0.002), more likely to be classified as moderate to severe (25.9% vs 9.1%; χ2=6.1,
P=0.01). There were no differences in terms of suicidal ideation, which was high for both groups of women (56.6%).
Older women had higher psychological symptoms on the MSAS scale form and significantly higher PHQ-9 depression
levels. A higher proportion of older women scored above the cut-off point for moderate to severe depression (9.2% vs
21.8%; χ2=3.7, P=0.048). Fewer older women had no mental health challenges (26.1% vs 42.4%) and more had multiple
comorbidities (P=0.07).
Conclusions: The vast majority of women reported experiencing a variety of physical and psychological menopause-related
symptoms and there was a high suicide ideation rate in both groups of women. Over half of the group of menopausal
women recorded distressing symptoms such as hot flushes, sweating, decreased sexual desire, back pain, night sweats,
avoiding intimacy, involuntary urination and skin changes, yet few sought help. Age-specific, psychosexual and menopause
services should be routinely available for women with HIV.
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Introduction
In the UK, approximately one-third of people accessing HIV care
are women [1]. There is a lack of data on the impact of HIV on
women, particularly on the impact of HIV on psychosocial and
emotional health. A limited number of studies and surveys have
revealed some interesting gender differences in terms of the
psychological effect of HIV. Women are reported to experience
more shame and guilt over having HIV infection [2]. In a UK study,
women had greater psychological and global symptom distress [3].
In that study, relational, sexual behaviour and quality-of-life factors
were similar for men and women, and although adherence levels
did not differ by gender they were sub-optimal in 56% of patients.
Women with HIV have been shown to achieve lower scores in terms
of quality of life than men [4–6] and HIV adversely affects their
sexual activity [7–9]. These issues can have a negative impact on
health-seeking behaviour, adherence to medications and clinical
outcomes with HIV treatment [10]. Decreased sexual desire, poor
sexual function and sexual inactivity are also common among
women infected with HIV [11]. Coping strategies, ability to disclose
HIV status to partners and to form new relationships as well as
empowerment to practice safe sex may be affected negatively by
HIV [9], though little is known about the current psychosexual
challenges faced by UK women with HIV infection.
There is a growing literature on the HIV ageing population.The advent
of highly successful HIV treatments, good adherence and improved
side-effect management have resulted in a growing HIV population,
enjoying good health while being exposed to the natural processes
of ageing. However, it is unclear how the ageing process affects people
living with HIV compared to those without HIV, how it differs – or
indeed if it does, and what service provision is required and available
for this emerging population. Although many studies have explored
men who have sex with men as they age, there is a dearth of literature
on women generally and age-specific challenges particularly, such
as menopause [12]. Menopause, and coping with ongoing menopause
symptoms is a challenge for women generally [13], heightened for
those facing HIV infection, especially given the ramification for sexual
behaviour. HIV is now a chronic disease thanks to the advances in
its treatment and subsequent dramatic decreases in morbidity and
mortality. As a result, many women with HIV survive to experience
menopause. There is some evidence to suggest that women with HIV
infection experience increased menopausal symptoms and
psychological concerns [14]. Yet a recent systematic review [12] could
only identify six studies with conflicting and inconclusive findings.
Of these, four were from the USA, one from Brazil and one from
France. Thus there were no data from the UK. The present study
addresses the lack of data on HIV and menopause in the UK for
women with HIV.
In this cross-sectional study, we aim to explore the challenges faced
by women with HIV in terms of psychosexual function, fertility,
and their experience during menopause.
Methods
Four research psychologists attended routine clinics in a large
outpatient HIV clinic, the Ian Charleson Day Centre, Royal Free
Hospital, London, and invited all women attenders to participate in
the study. A total of 272 women were approached and screened for
eligibility (age, language fluency, well enough to complete the
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questionnaire). Of the eligible participants (n=251), 170 accepted
to take part in the study (67.7% response rate). Usable completed
questionnaires were received from 140 women (55.8% response rate
from all approached). Among these women 57 were above the age
of 45 and included in the menopause-specific elements of the study.
Ethical approval was granted for the study (NRESC 13/LO/1214).
Measures
Participants were asked to complete a questionnaire about their
HIV status, length of HIV diagnosis and treatment, psychosexual
functioning and menopause. The questionnaire was constructed
to include questions on demographic information, general health,
standardised and validated scales on mental health and menopause
measures, together with service and treatment availability and
utilisation.
Anxiety
Participants completed the GAD-7, a self-administered
questionnaire used to measure anxiety [15]. The GAD-7 evaluates
anxiety over the preceding 2 weeks by scoring seven questions
on a four-point scale for a total score range of 0–21, with higher
scores reflecting a greater severity of symptoms.
Symptom burden
Symptoms included worrying too much, having trouble relaxing or
being restless. Scores of 5, 10 and 15 are considered as the cut-off
points for mild, moderate and severe anxiety respectively. Symptoms
were measured using the revised Memorial SymptomAssessment Scale
(MSAS-Short Form)[16], which has been used extensively in HIV
populations [17,18]. Four positive items were added to counterbalance
the scale negative effects, and included feeling reassured, optimistic,
strong and supported. An item on the presence of suicidal thoughts
was also added given the established elevated suicidal behaviours
noted in the literature among HIV-positive respondents. On the
standardised MSAS form, the frequency of all symptoms is scored
as follows: 1: rarely; 2: occasionally; 3: frequently; and 4: almost
constantly. The physical symptoms subscale is scored based on the
frequency of the 12 most prevalent physical symptoms. Symptoms
are rated on a five-point Likert scale (not at all: 0.8; a little bit: 1.6;
somewhat: 2.4; quite a bit: 3.2; very much: 4.0). The inventory
generates a Global Symptom Distress Index (MSAS GDI) and two
composite measures (physical symptoms and psychological symptoms
– MSAS Phys and MSAS Psych, respectively).
Depression
Depressive symptoms were examined using the PHQ-9 Depression
Test Questionnaire [19]. It evaluates the mood over the previous
2 weeks by scoring nine statements using a four-point scale (0:
not at all; 1: several days; 2: more than several days; 3: nearly
every day). The total score range in this study was 0–27, with
scores of 5, 10, 15 and 20 representing the cut-offs for mild,
moderate, moderately severe and severe depression, respectively.
Menopause
Women above the age of 45 years completed the Menopause
Specific Quality of Life questionnaire MENQOL [20]. This is the
cut-off age generally considered for menopause-related issues.
The questionnaire consists of 29 items in four groups: vasomotor:
psychosocial: physical and sexual [21].
Sexual functioning
Finally, women completed the Female Sexual Function Index (FSFI)
– a self-report instrument [22] consisting of 19 questions from
six groups: desire (2); arousal (4); lubrication (4); orgasm (3);
satisfaction (3); and pain (3). The 19 items are evaluated for the
past 4 weeks. The total score for FSFI is the sum of scores for
the six domains. Lower scores indicate greater severity of female
sexual dysfunction (FSD). A score of ≥23 shows normal sexual
function, 18–23 indicates mild FSD, 11–17 indicates moderate FSD
and ≤10 indicates severe FSD [23–25].
Analysis
Women of 45 years of age or over were considered to be in the
menopause age band and were compared to those aged under
45 years to examine age-specific differences using one-way
ANOVA tests and Chi-squared tests. In terms of the menopause-
specific question data reported by 57 women eligible for this
analysis, descriptive tests were used.
Results
The group of women of 45 years of age or over was compared
with the group below 45 years of age. The findings are set out
in Table 1 below.
There were no significant differences according to age for ethnic
origin. The majority of women (66.2% from the below 45 years
of age group and 68.4% from the above 45 years of age group)
recorded themselves as being of black ethnic origin. Similarly, there
were no differences by group for education status. Residence in
the UK was of prolonged duration, with a mean of 17 years for
the former group and 22 years for the latter (F(1)=4.89, P=0.03).
Average length of HIV diagnosis was approximately 12 years and
differed by group (14 years for the older group vs 10 years for
the younger group; F(1)=12.42, P=0.001). Older women were
significantly less likely to be in a relationship (χ2(1)=6.13, P=0.01),
and had higher anxiety scores (F(1)=9.57, P=0.002), with
significantly more scoring above the cut-off point for anxiety
classified as moderate to severe (25.9% vs 9.1%; χ2(1)=6.06,
P=0.01). There was no difference in the distribution of suicidal
ideation, but of note was the fact that over half of the women
(54.1% and 56.9%, respectively) reported suicidal ideation in the
previous week. Older women had significantly higher psychological
symptoms on the MSAS scale as well as significantly higher
depression levels on the PHQ-9 score. A significantly higher
proportion of older women scored above the cut-off point for
moderate to severe depression on the PHQ (21.8% vs 9.2%;
χ2(1)=3.70, P=0.048). When examining mental health comorbidity,
there was a tendency for fewer older women having no mental
health challenges (26.1% vs 42.4%) and more having multiple
comorbidities (two or three out of the three anxiety, depression
and suicidal ideation – 26.9% vs 8.5%; χ2(1)=7.03, P=0.07).
The MENQOL questionnaire evaluates the number of symptoms
women experience and the severity of each symptom. As shown
in Table 2, the vast majority of women reported experiencing a
variety of physical and psychological symptoms; however, the
severity of symptoms was within the mild range. Over three-
quarters felt tired (77.8%), 76.4% reported a lack of energy, 74.5%
that they accomplished less than they used to, 72.7% a decrease
in stamina, 71.4% weight gain, 69.6% poor memory, 67.9%
difficulty sleeping and 67.3% wanting to be alone.
Distressing symptoms such as hot flushes, sweating, decreased sexual
desire, back pain, night sweats, avoiding intimacy, involuntary urination
and skin changes were noted in over half the group of older women.
Of the 57 women, 35 had not sought help for their menopause
symptoms. For those who had, this came from their general
practitioner in four cases, the HIV clinic in 10, a gynaecologist in five,
and friends in three cases. Most had not considered taking any
treatment for these symptoms (35 out of 57). Only seven women
reported taking hormone replacement therapy, while eight had used
natural or herbal remedies. Five women reported using antidepressant
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medication. Five reported using vaginal oestrogen cream and 23
reported taking medication for bone density.
Discussion
Women attending a London HIV clinic tend to be of mixed
ethnicity, with the majority recording black ethnicity, yet members
of both age groups had resided in the UK for many years. The
overall mental health burden for this group is of note – with
many experiencing levels of anxiety and depression above the
cut-offs and a high level of past-week suicidal ideation. The
burden of HIV for women generally has been well recorded in
the literature, and these data endorse these findings [26,27].
However, the women attending this clinic may have good
access to specialised HIV and gender-related care, and this
group may not generalise to all women with HIV [28]. Recent
studies have indicated that there may be a burden of unmet
need [29] and that the insight into challenges and provision for
women is often skewed to focus on pregnancy with less literature
on the totality of women‘s age range.
This small-scale study of female attenders of an HIV outpatient
clinic in the UK‘s capital city shows the importance of age-
associated burdens. A recent review has highlighted that
menopause is an important consideration in the psychological
health of women with HIV [30]. Menopause-related issues are
particularly prevalent in this population and it is of note that there
is an unmet service need. Older women were significantly less likely
to be in a relationship so the concerns of loneliness are heightened
and the possibility of partner support reduced.
In terms of psychological burden, older women had higher anxiety
scores with more scoring above the cut-off point associated with
moderate to severe anxiety. This group of women had higher
psychological symptoms on the MSAS scale as well as higher
depression levels on the PHQ-9 score. A higher proportion of older
women scored above the cut-off point for moderate to severe
depression on the PHQ-9 Depression test questionnaire. When
examining mental health comorbidity, there was a tendency for fewer
older women to have no mental health challenges (42% vs 26%) and
more to have multiple comorbidities (two or three out of the three
anxiety, depression and suicidal ideation). Although age was not a
factor in suicidal ideation, over half of all women in the study reported
suicidal ideation in the previous week, which is extremely high and
an indicator of life challenges faced by all women with HIV.
In terms of menopause symptoms, the vast majority of women
reported experiencing a variety of physical and psychological
symptoms; however, the severity of symptoms was within the mild
range and the majority of women reported that they had not
sought help for these symptoms or for their management. In the
clinic where this study took place, there were dedicated menopause
services available, but this is generally not the case in most HIV
clinics, despite a growing need due to the ageing HIV population.
Table 1. Comparison of demographics and outcomes for women below and above 45 years of age
Full sample
(n=140)
Women aged
<45 years (n=69)
Women aged
≥45 years (n=57)
χ2 or F(df),
P value
Ethnicity
White 34 (25.0%) 17 (26.2%) 16 (28.1%) χ2(2)=0.99, P=0.61
Black 95 (69.9%) 43 (66.2%) 39 (68.4%)
Other ethnic minorities 7 (5.1%) 5 (7.7%) 2 (3.5%)
How long living in the UK (years) M=19.30 (SD=11.29) M=17.35 (SD=10.11) M=22.44 (SD=13.13) F(1)=4.89, P=0.03
Education level (last qualification achieved)
GCSEs 22 (17.3%) 8 (12.5%) 11 (21.6%) χ2(4)=1.84, P=0.76
A Levels 18 (14.2%) 9 (14.1%) 7 (13.7%)
Degree 42 (33.1%) 22 (34.4%) 16 (31.4%)
Postgraduate 23 (18.1%) 13 (20.3%) 8 (15.7%)
Other 22 (17.3%) 12 (18.8%) 9 (17.6%)
Relationship status
In a relationship 67 (51.5%) 43 (64.2%) 22 (41.5%) χ2(1)=6.13, P=0.01
Not in a relationship 63 (48.5%) 24 (35.8%) 31 (58.5%)
Length of diagnosis (years) M=11.54 (SD=6.43) M=9.64 (SD=5.37) M=13.74 (SD=6.76) F(1)=12.42, P=0.001
Anxiety GAD score M=4.64 (SD=5.34) M=3.29 (SD=3.74) M=6.15 (SD=6.28) F(1)=9.57, P=0.002
Anxiety GAD above cut-off point 23 (17.8%) 6 (9.1%) 14 (25.9%) χ2(1)=6.06, P=0.01
Symptoms – MSAS Psych score M=6.34 (SD=2.81) M=5.77 (SD=2.43) M=6.96 (SD=2.84) F(1)=5.38, P=0.02
Symptoms – MSAS total M=25.59 (SD=5.18) M=25.0 (SD=4.90) M=26.25(SD=5.25) F(1)=1.87, P=0.17
PHQ-9 score M=5.44 (SD=6.0) M=4.00 (SD=4.28) M=6.78 (SD=7.01) F(1)=7.12, P=0.009
PHQ-9 > cut-off point moderate + 22 (16.8%) 6 (9.2%) 12 (21.8%) χ2(1)=3.70, P=0.048
Suicidal thoughts in last week 69 (56.6%) 33 (54.1%) 29 (56.9%) χ2(1)=0.09, P=0.85
Combined mental health burden
None (PHQ/GAD/Suicidal) 38 (33.6%) 25 (42.4%) 12 (26.1%) χ2(1)=7.03, P=0.07
One out of three 55 (48.7%) 29 (49.2%) 22 (47.8%)
Two out of three 10 (8.8%) 3 (5.1%) 6 (13.0%)
Three out of three 10 (8.8%) 2 (3.4%) 6 (13.0%)
Note: totals for some demographic data may vary due to missing data.
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The majority of women in this study had not sought treatment
options, despite often distressing symptoms.
This cross-sectional study gives some insight into the psychological
burden in women. Despite the fact that older women recorded
more burden on some of the variables, it is of note that there
was high burden for the entire sample. It may well be that
menopause is not the driving factor for such burden, but acts as
an added complication to the many difficulties that women may
encounter, including HIV diagnosis, treatment navigation, side-
effect burden, stigma, relationship strain and the burden of varied
physical symptoms. Yet our data clearly indicate that with
advancing age, menopausal issues are of concern to women and
pathways to care and support are needed. This may well be of
greater need in areas where less provision exists. Appropriate
adaptations of generalised services for women need to be included
in the range of general and specific HIV services.
This study highlights the importance of considering the
psychological burden of menopause and its symptoms in women
with HIV, and the need for increased psychological care and
support. It also highlights the very specific needs of older women
and suggests that routine documentation and enquiry of
psychological state is an important part of care with associated
services being made available.
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Table 2. Reported severity of menopausal symptoms experienced in
the past month (MENQOL)
Proportion
of symptoms
Severity scale
(range 1–8)
n (% yes) M (SD)
Feeling tired or worn out 42 (77.8%) 3.4 (2.0)
Feeling a lack of energy 42 (76.4%) 3.0 (2.1)
Accomplishing less than I used to 41 (74.5%) 2.7 (2.1)
Decrease in stamina 40 (72.7%) 3.0 (2.2)
Weight gain 40 (71.4%) 2.8 (2.3)
Experiencing poor memory 39 (69.6%) 2.6 (2.1)
Difficulty sleeping 36 (67.9%) 3.2 (2.4)
Feelings of wanting to be alone 37 (67.3%) 2.2 (2.1)
Feeling anxious or nervous 34 (63.0%) 2.6 (2.2)
Change in your sexual desire 33 (62.3%) 2.4 (2.6)
Being dissatisfied with personal life 35 (61.4%) 2.1 (2.1)
Feeling depressed, down or blue 34 (61.8%) 2.5 (2.1)
Night sweats 34 (60.7%) 3.0 (2.5)
Being impatient with other people 33 (60.0%) 2.9 (2.4)
Low backache 33 (58.9%) 3.2 (2.2)
Sweating 32 (58.2%) 2.9 (2.6)
Feeling bloated 32 (58.2%) 2.2 (2.2)
Avoiding intimacy 29 (58.0%) 2.4 (2.7)
Hot flushes 31 (55.4%) 2.8 (2.6)
Involuntary urination when
coughing or laughing
30 (53.6%) 2.3 (2.5)
Changes in appearance, texture or
tone of your skin
29 (52.7%) 1.9 (2.3)
Drying skin 29 (52.7%) 2.3 (2.5)
Vaginal dryness during intercourse 22 (44.0%) 2.1 (2.7)
Increased facial hair 23 (43.4%) 1.1 (2.0)
Flatulence (wind) or gas pains 29 (36.4%) 2.4 (2.0)
Aching muscles and joints 41 (29.3%) 3.6 (2.1)
Decrease in physical strength 40 (28.6%) 2.9 (2.2)
Aches in back of neck or head 38 (27.1%) 3.3 (2.2)
Frequent urination 28 (20.0%) 3.0 (2.3)
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